August Global News
Industry news tidbits from around the world.
- Quanticate, a UK-based CRO announced its expansion into the United States via new offices in Cambridge, MA. Earlier this year, the company announced its formation as the merger of two CROs: Statwood and Oxford Pharmaceutical Sciences. It has over 200 employees on three continents.
- Synergy Research Group (Moscow) and Metrics Research (Karachi, Pakistan) have established a CRO alliance. The Metrics' alliance extends Synergy's ability to offer global trial capabilities to sponsors. It already has alliances in Europe, India, the United States, and the Ukraine.
- Lombardia, Italy, is the recipient of a multiyear project to establish a Center of Excellence for Clinical Research. The Lombardia Ministry of Health chose the expertise of the Clinical Research Consortium of Massachusetts (CRCM), which was tapped by the Massachusetts Office of International Trade and Investment (MOITI). Consortium members include BBK Worldwide, Court Square Group, Phase Forward, and Tufts Medical Center's Institute for Clinical Research & Health Policy Studies. CRCM members and MOITI are also pitching the Centers of Excellence for Clinical Research plan to three Latin American countries and two others in Europe.
- European Pharmaceutical Industry Association's (Brussels, Belgium) new Code of Practice went into effect, requiring each company to make publicly available a list of patient organizations to which it provides direct or indirect financial support, or significant nonfinancial support.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
